7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | GCP-Service International West GmbH | 46 | 2023-06-05 | 2026-10-02 |
| Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg - Myelofibrosis | Phase 2 | Completed | Geron Corporation | 107 | 2015-08-28 | 2021-09-14 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Imetelstat - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Geron Corporation | 80 | 2012-10-29 | 2021-09-21 |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Imetelstat - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Completed | Geron Corporation | 20 | 2010-12-01 | 2016-01-26 |
| Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) - Multiple Myeloma | Phase 2 | Completed | Geron Corporation | 13 | 2010-11-01 | 2026-06-17 |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Imetelstat sodium, Bevacizumab, Paclitaxel - Locally Recurrent or Metastatic Breast Cancer | Phase 2 | Completed | Geron Corporation | 166 | 2010-11-01 | 2016-01-26 |
| Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) imetelstat, Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Completed | Geron Corporation | 116 | 2010-05-01 | 2016-01-26 |
Myelodysplastic Syndromes (2) · Primary Myelofibrosis (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Neoplasms, Plasma Cell (1) · Polycythemia Vera (1) · Recurrence (1) · Thrombocythemia, Essential (1)
Geron Corporation (6) · GCP-Service International West GmbH (1)
United States (6) · Germany (4) · Canada (3) · France (2) · Australia (1) · Belgium (1) · Israel (1) · Italy (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Carol Ann Huff, M.D. (1) · Joan Schiller, MD (1) · Joe Eid (1) · Kathy Miller, MD (1) · Ted Shih, PharmD (1) · Uwe Platzbecker, MD (1)
PMID 26332545, PMID 26332546, PMID 32732354, PMID 34138638
2015 (1)